Novo Nordisk

Novo Nordisk NVO Stock

$39.50   -2.948405%
Add to favorites
Exchange
Market Cap
$174.09B
LOW - HIGH [24H]
$39.32 - $40.57
VOLUME [24H]
$13.99M
P/E Ratio
9.97
Earnings per share
$3.96
ISIN
US6701002056
Price   Prediction

Novo Nordisk Price Chart

Sorry, that's all we've gotfor now...

Novo Nordisk (NVO) stock price today is 39.5 USD on NYSE (-2.95% on the day). Updated .

Novo Nordisk NVO Financial and Trading Overview

Novo Nordisk stock price 39.5 USD
Previous Close 41.6 USD
Open 40.72 USD
Bid 0 USD x 170000
Ask 0 USD x 220000
Day's Range 40.23 - 40.96 USD
52 Week Range 35.12 - 64.16 USD
Volume 17.57M USD
Avg. Volume 12.39M USD
Market Cap 179.38B USD
Beta (5Y Monthly) 0.368
PE Ratio (TTM) 10.277778
EPS (TTM) 3.96 USD
Forward Dividend & Yield 1.8 (4.40%)
Ex-Dividend Date August 17, 2026
1y Target Est 45.68 USD

NVO Valuation Measures

Enterprise Value 267.58B USD
Trailing P/E 10.277778
Forward P/E 11.587383
PEG Ratio (5 yr expected) 4.33
Price/Sales (ttm) 0.5376273
Price/Book (mrq) 5.482786
Enterprise Value/Revenue 0.802
Enterprise Value/EBITDA 1.474

Trading Information

Novo Nordisk Stock Price History

Beta (5Y Monthly) 0.368
52-Week Change -12.51%
S&P500 52-Week Change 12.07%
52 Week High 64.16 USD
52 Week Low 35.12 USD
50-Day Moving Average 39.99 USD
200-Day Moving Average 43.09 USD

NVO Share Statistics

Avg. Volume (3 month) 12.39M USD
Avg. Daily Volume (10-Days) 14.01M USD
Shares Outstanding 3.33B
Float 3.16B
Short Ratio 3.41
% Held by Insiders 0.0030%
% Held by Institutions 10.11%
Shares Short 38.29M
Short % of Float 1.20%
Short % of Shares Outstanding 0.86%

Dividends & Splits

Trailing Annual Dividend Rate 11.7
Trailing Annual Dividend Yield 28.12%
5 Year Average Dividend Yield 152.00%
Payout Ratio 0.45360002
Last Split Factor 2:1

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 33.92%
Operating Margin (ttm) 50.77%
Gross Margin 83.33%
EBITDA Margin 54.41%

Management Effectiveness

Return on Assets (ttm) 19.05%
Return on Equity (ttm) 58.38%

Income Statement

Revenue (ttm) 333.65B USD
Revenue Per Share (ttm) 75.25 USD
Quarterly Revenue Growth (yoy) 5.60%
Gross Profit (ttm) 278.04B USD
EBITDA 181.56B USD
Net Income Avi to Common (ttm) 113.18B USD
Diluted EPS (ttm) 3.96
Quarterly Earnings Growth (yoy) -16.30%

Balance Sheet

Total Cash (mrq) 46.35B USD
Total Cash Per Share (mrq) 10.51 USD
Total Debt (mrq) 134.48B USD
Total Debt/Equity (mrq) 61.74 USD
Current Ratio (mrq) 0.845
Book Value Per Share (mrq) 7.423233

Cash Flow Statement

Operating Cash Flow (ttm) 127.33B USD
Levered Free Cash Flow (ttm) 32.75B USD

Profile of Novo Nordisk

Country United States
State N/A
City Bagsvaerd
Address Novo Alle 1
ZIP 2880
Phone 45 44 44 88 88
Website https://www.novonordisk.com
Industry Drug Manufacturers - General
Sector(s) Healthcare
Full Time Employees 68794

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Q&A For Novo Nordisk Stock

What is a current NVO stock price?

Novo Nordisk NVO stock price today per share is 39.5 USD.

How to purchase Novo Nordisk stock?

You can buy NVO shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Novo Nordisk?

The stock symbol or ticker of Novo Nordisk is NVO.

Which industry does the Novo Nordisk company belong to?

The Novo Nordisk industry is Drug Manufacturers - General.

How many shares does Novo Nordisk have in circulation?

The max supply of Novo Nordisk shares is 4.41B.

What is Novo Nordisk Price to Earnings Ratio (PE Ratio)?

Novo Nordisk PE Ratio is 9.97474800 now.

What was Novo Nordisk earnings per share over the trailing 12 months (TTM)?

Novo Nordisk EPS is 3.96 USD over the trailing 12 months.

Which sector does the Novo Nordisk company belong to?

The Novo Nordisk sector is Healthcare.

Novo Nordisk NVO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech OMX CRD Global Sustainab QCRD US 1595.1 USD —
0
— — — — — — — — —
us NYSE Arca Pharmaceutical Index DRG US 1344.12 USD —
-2.13
— — 1340.56 USD — 1373.02 USD — — — —
us NYSE Composite Index NYA US 23574.9 USD —
-1
— — 23530.84 USD — 23742.73 USD — — — —
$2.16T
Total marketcap
$70.95B
Total volume
BTC 57.99%   •   ETH 9.89%
Dominance
Select currency